Transcatheter Aortic Valve Replacement Prognostication with Augmented Mean Arterial Pressure.
STS risk score
aortic valve stenosis
augmented mean arterial pressure
mortality
transcatheter aortic valve replacement (TAVR)
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
26 Apr 2023
26 Apr 2023
Historique:
received:
29
03
2023
revised:
19
04
2023
accepted:
21
04
2023
medline:
26
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
Post-transcatheter aortic valve replacement (TAVR) patient outcome is an important research topic. To accurately assess post-TAVR mortality, we examined a family of new echo parameters (augmented systolic blood pressure (AugSBP) and arterial mean pressure (AugMAP)) derived from blood pressure and aortic valve gradients. Patients in the Mayo Clinic National Cardiovascular Diseases Registry-TAVR database who underwent TAVR between 1 January 2012 and 30 June 2017 were identified to retrieve baseline clinical, echocardiographic and mortality data. AugSBP, AugMAP and valvulo-arterial impedance (Zva) (Zva) were evaluated using Cox regression. Receiver operating characteristic curve analysis and the c-index were used to assess the model performance against the Society of Thoracic Surgeons (STS) risk score. The final cohort contained 974 patients with a mean age of 81.4 ± 8.3 years old, and 56.6% were male. The mean STS risk score was 8.2 ± 5.2. The median follow-up duration was 354 days, and the one-year all-cause mortality rate was 14.2%. Both univariate and multivariate Cox regression showed that AugSBP and AugMAP parameters were independent predictors for intermediate-term post-TAVR mortality (all Augmented mean arterial pressure provides clinicians with a simple but effective approach to quickly identify patients at risk and potentially improve post-TAVR prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Post-transcatheter aortic valve replacement (TAVR) patient outcome is an important research topic. To accurately assess post-TAVR mortality, we examined a family of new echo parameters (augmented systolic blood pressure (AugSBP) and arterial mean pressure (AugMAP)) derived from blood pressure and aortic valve gradients.
METHODS
METHODS
Patients in the Mayo Clinic National Cardiovascular Diseases Registry-TAVR database who underwent TAVR between 1 January 2012 and 30 June 2017 were identified to retrieve baseline clinical, echocardiographic and mortality data. AugSBP, AugMAP and valvulo-arterial impedance (Zva) (Zva) were evaluated using Cox regression. Receiver operating characteristic curve analysis and the c-index were used to assess the model performance against the Society of Thoracic Surgeons (STS) risk score.
RESULTS
RESULTS
The final cohort contained 974 patients with a mean age of 81.4 ± 8.3 years old, and 56.6% were male. The mean STS risk score was 8.2 ± 5.2. The median follow-up duration was 354 days, and the one-year all-cause mortality rate was 14.2%. Both univariate and multivariate Cox regression showed that AugSBP and AugMAP parameters were independent predictors for intermediate-term post-TAVR mortality (all
CONCLUSIONS
CONCLUSIONS
Augmented mean arterial pressure provides clinicians with a simple but effective approach to quickly identify patients at risk and potentially improve post-TAVR prognosis.
Identifiants
pubmed: 37233159
pii: jcdd10050192
doi: 10.3390/jcdd10050192
pmc: PMC10218897
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Am Heart Assoc. 2019 Nov 5;8(21):e014020
pubmed: 31665959
Circ Cardiovasc Interv. 2017 Nov;10(11):
pubmed: 29127116
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):242-250
pubmed: 32353143
Heart Vessels. 2019 Jun;34(6):1031-1039
pubmed: 30599060
J Am Coll Cardiol. 2021 Feb 2;77(4):e25-e197
pubmed: 33342586
Am J Physiol Heart Circ Physiol. 2020 Dec 1;319(6):H1451-H1458
pubmed: 33064556
J Invasive Cardiol. 2020 Apr;32(4):129-137
pubmed: 32198316
J Am Coll Cardiol. 2020 Apr 21;75(15):1758-1769
pubmed: 32299587
Bioinformatics. 2008 Oct 1;24(19):2200-8
pubmed: 18635567
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Yonsei Med J. 2020 Jun;61(6):482-491
pubmed: 32469172
J Am Coll Cardiol. 2009 Sep 8;54(11):1003-11
pubmed: 19729117
Sci Rep. 2020 Sep 23;10(1):15568
pubmed: 32968104
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Cardiovasc Revasc Med. 2021 Mar;24:33-41
pubmed: 32855083
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
J Am Soc Echocardiogr. 2009 Jan;22(1):1-23; quiz 101-2
pubmed: 19130998
JACC Cardiovasc Interv. 2013 May;6(5):472-8
pubmed: 23602460
J Am Soc Echocardiogr. 2013 Jul;26(7):691-8
pubmed: 23669595
Circ Cardiovasc Interv. 2020 Jan;13(1):e008372
pubmed: 31937136
J Am Soc Echocardiogr. 2012 Apr;25(4):444-53
pubmed: 22244001
Interact Cardiovasc Thorac Surg. 2013 Aug;17(2):359-64
pubmed: 23644728
JACC Cardiovasc Interv. 2016 Nov 14;9(21):2189-2199
pubmed: 27832844
Ann Thorac Surg. 2015 Aug;100(2):516-21
pubmed: 26052059
J Invasive Cardiol. 2017 Mar;29(3):109-114
pubmed: 28255105
Circ Cardiovasc Imaging. 2017 Jul;10(7):
pubmed: 28701528
J Am Coll Cardiol. 2009 Sep 8;54(11):1012-3
pubmed: 19729118
Circ Cardiovasc Imaging. 2013 Nov;6(6):1024-31
pubmed: 24036387